Trials / Completed
CompletedNCT02555397
Phase 1 Trial of Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer
Phase 1 Trial of Oncolytic Adenovirus-Mediated Cytotoxic and Interleukin 12 Gene Therapy for Locally Recurrent Prostate Cancer After Definitive Radiotherapy
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 15 (actual)
- Sponsor
- Henry Ford Health System · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary purpose of this phase 1 study is to determine the dose-dependent toxicity and maximum tolerated dose (MTD) of oncolytic adenovirus-mediated cytotoxic and IL-12 gene therapy in men with locally recurrent prostate cancer after definitive radiotherapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| BIOLOGICAL | Ad5-yCD/mutTKSR39rep-hIL12 | Single intraprostatic injection of Ad5-yCD/mutTKSR39rep-hIL12 on day 1 |
Timeline
- Start date
- 2015-08-01
- Primary completion
- 2019-06-16
- Completion
- 2024-01-22
- First posted
- 2015-09-21
- Last updated
- 2024-10-10
- Results posted
- 2024-10-10
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT02555397. Inclusion in this directory is not an endorsement.